<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01183013</url>
  </required_header>
  <id_info>
    <org_study_id>1264.3</org_study_id>
    <secondary_id>2008-008127-15</secondary_id>
    <nct_id>NCT01183013</nct_id>
  </id_info>
  <brief_title>30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks</brief_title>
  <official_title>A Randomised, Double-blind Parallel Group Study to Compare the Efficacy and Safety of Initial Combination Therapy With Linagliptin 5 mg + Pioglitazone 15 mg, 30 mg, or 45 mg, vs. Monotherapy With Pioglitazone (15 mg, 30 mg, or 45 mg) or Linagliptin 5 mg Once Daily for 30 Weeks, Followed by a Blinded Trial Period on Linagliptin 5 mg + Pioglitazone 30 or 45 mg Versus Pioglitazone Monotherapy 30 or 45 mg or Linagliptin 5 mg for up to 54 Weeks in Type 2 Diabetic Patients With Insufficient Glycaemic Control on Diet and Exercise</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The primary objective is to demonstrate superior glycaemic control (HbA1c reduction) after 30
      weeks of linagliptin/pioglitazone (5/15, 5/30 and 5/45 mg) versus the respective individual
      monotherapies of pioglitazone (15 mg, 30 mg, or 45 mg, administered orally once daily), and
      linagliptin (5 mg, administered orally once daily). In addition, durability of treatment
      effect and safety under chronic treatment conditions will be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">February 2013</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in HbA1c After 30 Weeks of Treatment.</measure>
    <time_frame>Baseline and 30 weeks</time_frame>
    <description>HbA1c is measured as a percentage. The change from baseline is the Week 30 HbA1c minus the baseline HbA1c.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of &lt; 7.0% After 30 Weeks of Treatment</measure>
    <time_frame>Baseline and 30 weeks</time_frame>
    <description>Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of &lt; 6.5% After 30 Weeks of Treatment</measure>
    <time_frame>Baseline and 30 weeks</time_frame>
    <description>Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 30 Weeks of Treatment)</measure>
    <time_frame>Baseline and 30 weeks</time_frame>
    <description>Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c Change From Baseline by Visit Over Time</measure>
    <time_frame>Baseline, week 6, week 12, week 18, week 24, week 30</time_frame>
    <description>HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes fixed effects for treatment, continuous baseline HbA1c, prior andi-diabetic medication, country, visit and treatment.
by visit interaction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG) Change From Baseline After 30 Weeks of Treatment</measure>
    <time_frame>Baseline and 30 weeks</time_frame>
    <description>The change from baseline is the FPG after 30 weeks minus the baseline FPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Plasma Glucose (FPG) Change From Baseline by Visit Over Time</measure>
    <time_frame>Baseline, week 6, week 12, week 18, week 24, week 30</time_frame>
    <description>The change from baseline is the FPG over time minus the baseline FPG. Model includes fixed effects for treatment, continuous baseline FPG, continuous baseline HbA1c, prior anti-diabetic medication, country, visit and treatment by visit interaction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Two-hour Postprandial Glucose (2hPPG) Change From Baseline at Week 30 by Meal Tolerance Test (MTT)</measure>
    <time_frame>Baseline and 30 weeks</time_frame>
    <description>The change from baseline is the 2hPPG after 30 weeks minus the baseline 2hPPG.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Use of Rescue Therapy</measure>
    <time_frame>30 weeks</time_frame>
    <description>Proportion of patients at 30 weeks with rescue therapy using Kaplan-Meier analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Rescue Therapy During the First 30 Weeks of Treatment</measure>
    <time_frame>30 weeks</time_frame>
    <description>Rescue therapy was defined to include any new antidiabetic medication taken for hyperglycemia and introduced on or after the start date of study treatment and before the end date of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">936</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Pioglitazone 15 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone Capsules 15 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 30 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone Capsules 30 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pioglitazone 45 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone Capsules 45 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Linagliptin 5mg Tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin 5mg / Pioglitazone 15 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin 5mg / Pioglitazone 15 mg Tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin 5mg / Pioglitazone 30 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin 5mg / Pioglitazone 30 mg Tablets once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linagliptin 5mg / Pioglitazone 45 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Linagliptin 5mg / Pioglitazone 45 mg Tablets once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 15 mg</intervention_name>
    <description>Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks</description>
    <arm_group_label>Pioglitazone 15 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 45 mg</intervention_name>
    <description>Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks</description>
    <arm_group_label>Pioglitazone 45 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone 30 mg</intervention_name>
    <description>Pioglitazone Capsules 30 mg once daily for up to 84 weeks</description>
    <arm_group_label>Pioglitazone 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin 5mg / Pioglitazone 45 mg FDC</intervention_name>
    <description>Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks</description>
    <arm_group_label>Linagliptin 5mg / Pioglitazone 45 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin 5mg / Pioglitazone 30 mg FDC</intervention_name>
    <description>Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks</description>
    <arm_group_label>Linagliptin 5mg / Pioglitazone 30 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin 5mg</intervention_name>
    <description>Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks</description>
    <arm_group_label>Linagliptin 5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linagliptin 5mg / Pioglitazone 15 mg FDC</intervention_name>
    <description>Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks</description>
    <arm_group_label>Linagliptin 5mg / Pioglitazone 15 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Diagnosis of type 2 diabetes mellitus prior to informed consent

          2. Male and female patients with insufficient glycaemic control (HbA1c &gt;= 7.0 to &lt;= 10.5%
             at Visit 2) on diet and exercise alone, without oral antidiabetic drug therapy within
             10 weeks prior to start of the run-in period (date of Visit 2)

          3. Age &gt;= 18 and &lt;= 80 years at start date of Visit 1 (Screening)

          4. BMI &lt;= 45 kg/m2 (Body Mass Index) at start date of Visit 1 (Screening)

          5. Signed and dated written informed consent by start date of Visit 1 in accordance with
             GCP and local legislation

        Exclusion criteria:

          1. Uncontrolled hyperglycaemia with a confirmed glucose level &gt; 240 mg/dl (&gt; 13.3 mmol/l)
             after an overnight fast during screening or placebo run-in period (cf. Section
             3.3.4.1)

          2. Myocardial infarction within 6 months, stroke or TIA within 3 months prior to informed
             consent

          3. Clinical evidence of active liver disease (e.g. jaundice) or the ALT level &gt; 2.5 times
             the upper limit of normal (according to pioglitazone label)

          4. Bariatric surgery, performed within the past 2 years prior to informed consent or
             planned at the time of informed consent

          5. Gastrointestinal surgeries prior to informed consent that induce chronic malabsorption

          6. Known hypersensitivity or allergy to the investigational products (linagliptin and/or
             pioglitazone) or their excipients (including matching placebos)

          7. Contraindications to pioglitazone as defined in the local prescribing information
             (SPC), particularly :

               -  Diagnose of heart failure or history of heart failure

               -  Haemodialysis patients, due to limited experience with pioglitazone

          8. Treatment with gemfibrozil, montelukast, trimethoprim, or rifampicin - according to
             pioglitazone label and respective restrictions in Section 4.2.2

          9. Treatment with rosiglitazone, pioglitazone, GLP-1 analogues, or insulin within 3
             months prior to informed consent

         10. Treatment with anti-obesity drugs (e.g. sibutramine, orlistat) 3 months prior to
             informed consent

         11. Alcohol or drug abuse within the 3 months prior to informed consent or history of
             alcoholism

         12. Current treatment with systemic corticosteroids at time of informed consent or change
             in dosage of thyroid hormones within 6 weeks prior to informed consent

         13. Participation in another trial with an investigational drug within 30 days prior to
             informed consent

         14. Any other clinical condition as judged by the investigator that would not allow the
             safe completion of the protocol, e.g. inability of patients to comply with study
             procedures

         15. Pre-menopausal women (last menstruation &lt;= 1 year prior to informed consent) who:

               -  are nursing or pregnant or

               -  are of child-bearing potential (i.e. not permanently sterilised) and are not
                  practicing a highly effective method of birth control, or do not plan to continue
                  using this method throughout the study and do not agree to submit to periodic
                  pregnancy testing during participation in the trial.

             A highly effective method of birth control is defined - according to the Note for
             Guidance on non-clinical safety studies for the conduct of human trials for
             pharmaceuticals (CPMP/ICH/286/95, modification) - as those which result in a low
             failure rate (i. e. less than 1% per year) when used consistently and correctly such
             as implants, injectables, combined oral contraceptives, hormonal intrauterine
             devices/systems (IUDs/IUSs), sexual abstinence or vasectomised partner

         16. Symptomatic gallbladder disease in the last six months

         17. Medical history of pancreatitis.

         18. Patients with urinary bladder cancer or a history of urinary bladder cancer or
             uninvestigated macroscopic haematuria

         19. Any other contraindication or restriction for use of pioglitazone in accordance with
             the local prescribing information for pioglitazone.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1264.3.01026 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01020 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01062 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01064 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01049 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01078 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01037 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01065 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Rancho Cucamonga</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01059 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01023 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tarzana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01016 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01058 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01083 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norwalk</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01035 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01015 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01082 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01036 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Longwood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01038 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01042 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01079 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01018 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>St. Cloud</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01055 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01061 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01074 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01084 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Cartersville</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01060 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Perry</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01050 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01077 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01052 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Brownsburg</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01075 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01076 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01073 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Franklin</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sunset</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01069 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hyattsville</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01066 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01057 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Great Falls</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01045 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01044 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01022 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Zanesville</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01051 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fleetwood</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01025 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01081 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Greer</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01017 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01067 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01039 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01041 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01047 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01070 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01040 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Killeen</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01048 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01030 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01071 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>North Richland Hills</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01085 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01046 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.01056 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37207 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Harju</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37209 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Pärnu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37201 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37202 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37208 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37203 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37204 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37205 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tallin</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37206 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37210 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Viljandi County</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.49001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bad Lauterberg / Harz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.49007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dietzenbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.49002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.49009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.49003 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.49012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ingelheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.49008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.49005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.49010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Offenbach</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.49004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Stuhr</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37105 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37112 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37113 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37110 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Jelgava</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37101 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Liepaja</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37106 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ogre</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37104 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37108 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37109 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37111 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37107 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Talsi</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37102 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tukums</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.37103 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valmiera</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34013 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Badía del Vallès - Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34005 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Borges del Camp- Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34006 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Canet de Mar - Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34010 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Centelles - Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34004 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat - Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34009 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34002 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Sant Adrià del Besós- Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Tarrega - Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.34011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Vic - Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Annan</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44028 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Ash Vale, Aldershot</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44029 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Baillieston, Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44008 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Balham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44021 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Bradford on Avon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44019 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Burbage</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44012 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44027 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chestfield, Whitstable</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44011 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Chippenham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44033 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Johnstone</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44007 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Midsomer Norton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44034 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Paisley</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1264.3.44031 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Warminster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Germany</country>
    <country>Latvia</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>India</country>
    <country>Taiwan</country>
  </removed_countries>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2010</study_first_submitted>
  <study_first_submitted_qc>August 16, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2010</study_first_posted>
  <results_first_submitted>March 12, 2014</results_first_submitted>
  <results_first_submitted_qc>March 14, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <last_update_submitted>October 9, 2014</last_update_submitted>
  <last_update_submitted_qc>October 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Linagliptin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>After Amendment #5, patients were considered COMPLETED at the end of Part A (30 weeks) or after their next Part B visit (up to 54 weeks) if already in Part B. Before Amendment #5, all patients were considered COMPLETED at the end of Part A + Part B (84 weeks).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pio15/Pio30</title>
          <description>Participants treated with pioglitazone 15mg for 30 weeks followed by pioglitazone 30mg for up to 54 weeks.</description>
        </group>
        <group group_id="P2">
          <title>Pio30/Pio30</title>
          <description>Participants treated with pioglitazone 30mg for 30 weeks followed by pioglitazone 30mg for up to 54 weeks.</description>
        </group>
        <group group_id="P3">
          <title>Pio45/Pio45</title>
          <description>Participants treated with pioglitazone 30 mg for 6 weeks and then were titrated up to pioglitazone 45mg for 24 weeks followed by pioglitazone 45mg for up to 54 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Lina5/Lina5</title>
          <description>Participants treated with linagliptin 5mg once daily for 30 weeks followed by linagliptin 5mg once daily for up to 54 weeks.</description>
        </group>
        <group group_id="P5">
          <title>Lina5Pio15/Lina5Pio30</title>
          <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for 30 weeks followed by linagliptin 5mg + pioglitazone 30mg FDC for up to 54 weeks.</description>
        </group>
        <group group_id="P6">
          <title>Lina5Pio30/Lina5Pio30</title>
          <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for 30 weeks followed by linagliptin 5mg + pioglitazone 30mg FDC for up to 54 weeks.</description>
        </group>
        <group group_id="P7">
          <title>Lina5Pio45/Lina5Pio45</title>
          <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for 6 weeks and linagliptin 5mg + pioglitazone 45mg FDC for 24 weeks followed by linagliptin 5mg + pioglitazone 45mg FDC for up to 54 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="140"/>
                <participants group_id="P3" count="138"/>
                <participants group_id="P4" count="135"/>
                <participants group_id="P5" count="126"/>
                <participants group_id="P6" count="133"/>
                <participants group_id="P7" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="86">Completed is first 30 weeks (Part A) or up to 84 weeks in relation to Protocol Amendment #5</participants>
                <participants group_id="P2" count="101">Completed is first 30 weeks (Part A) or up to 84 weeks in relation to Protocol Amendment #5</participants>
                <participants group_id="P3" count="97">Completed is first 30 weeks (Part A) or up to 84 weeks in relation to Protocol Amendment #5</participants>
                <participants group_id="P4" count="105">Completed is first 30 weeks (Part A) or up to 84 weeks in relation to Protocol Amendment #5</participants>
                <participants group_id="P5" count="90">Completed is first 30 weeks (Part A) or up to 84 weeks in relation to Protocol Amendment #5</participants>
                <participants group_id="P6" count="88">Completed is first 30 weeks (Part A) or up to 84 weeks in relation to Protocol Amendment #5</participants>
                <participants group_id="P7" count="96">Completed is first 30 weeks (Part A) or up to 84 weeks in relation to Protocol Amendment #5</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="39"/>
                <participants group_id="P3" count="41"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="36"/>
                <participants group_id="P6" count="45"/>
                <participants group_id="P7" count="37"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="10"/>
                <participants group_id="P7" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="7"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reasons other than stated above</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="15"/>
                <participants group_id="P7" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients from the Full Analysis Set (FAS) which includes those patients in the treated set who had a baseline HbA1c value and at least one on-treatment HbA1c value.</population>
      <group_list>
        <group group_id="B1">
          <title>Pio15/Pio30</title>
          <description>Participants treated with pioglitazone 15mg for 30 weeks followed by pioglitazone 30mg for up to 54 weeks.</description>
        </group>
        <group group_id="B2">
          <title>Pio30/Pio30</title>
          <description>Participants treated with pioglitazone 30mg for 30 weeks followed by pioglitazone 30mg for up to 54 weeks.</description>
        </group>
        <group group_id="B3">
          <title>Pio45/Pio45</title>
          <description>Participants treated with pioglitazone 30 mg for 6 weeks and then were titrated up to pioglitazone 45mg for 24 weeks followed by pioglitazone 45mg for up to 54 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Lina5/Lina5</title>
          <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for 30 weeks followed by linagliptin 5mg + pioglitazone 30mg FDC for up to 54 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Lina5Pio15/Lina5Pio30</title>
          <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for 30 weeks followed by a blinded trial period on linagliptin 5mg + pioglitazone 30mg FDC</description>
        </group>
        <group group_id="B6">
          <title>Lina5Pio30/Lina5Pio30</title>
          <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for 30 weeks followed by linagliptin 5mg + pioglitazone 30mg FDC for up to 54 weeks.</description>
        </group>
        <group group_id="B7">
          <title>Lina5Pio45/Lina5Pio45</title>
          <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for 6 weeks and linagliptin 5mg + pioglitazone 45mg FDC for 24 weeks followed by linagliptin 5mg + pioglitazone 45mg FDC for up to 54 weeks.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
            <count group_id="B2" value="134"/>
            <count group_id="B3" value="134"/>
            <count group_id="B4" value="130"/>
            <count group_id="B5" value="120"/>
            <count group_id="B6" value="125"/>
            <count group_id="B7" value="126"/>
            <count group_id="B8" value="893"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.4" spread="10.4"/>
                    <measurement group_id="B2" value="57.2" spread="11.1"/>
                    <measurement group_id="B3" value="56.5" spread="11.1"/>
                    <measurement group_id="B4" value="56.3" spread="10.1"/>
                    <measurement group_id="B5" value="57.1" spread="10.2"/>
                    <measurement group_id="B6" value="56.4" spread="10.0"/>
                    <measurement group_id="B7" value="60.1" spread="10.2"/>
                    <measurement group_id="B8" value="57.1" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="66"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="54"/>
                    <measurement group_id="B6" value="61"/>
                    <measurement group_id="B7" value="57"/>
                    <measurement group_id="B8" value="410"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="68"/>
                    <measurement group_id="B4" value="79"/>
                    <measurement group_id="B5" value="66"/>
                    <measurement group_id="B6" value="64"/>
                    <measurement group_id="B7" value="69"/>
                    <measurement group_id="B8" value="483"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline HbA1c</title>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.33" spread="0.93"/>
                    <measurement group_id="B2" value="7.99" spread="0.85"/>
                    <measurement group_id="B3" value="8.12" spread="0.87"/>
                    <measurement group_id="B4" value="8.01" spread="0.88"/>
                    <measurement group_id="B5" value="8.13" spread="0.94"/>
                    <measurement group_id="B6" value="8.17" spread="1.07"/>
                    <measurement group_id="B7" value="8.01" spread="0.81"/>
                    <measurement group_id="B8" value="8.11" spread="0.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline fasting plasma glucose (FPG)</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="171.3" spread="39.3"/>
                    <measurement group_id="B2" value="165.8" spread="40.0"/>
                    <measurement group_id="B3" value="167.5" spread="37.9"/>
                    <measurement group_id="B4" value="161.4" spread="38.1"/>
                    <measurement group_id="B5" value="167.3" spread="39.5"/>
                    <measurement group_id="B6" value="168.8" spread="46.8"/>
                    <measurement group_id="B7" value="162.3" spread="36.8"/>
                    <measurement group_id="B8" value="166.3" spread="39.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in HbA1c After 30 Weeks of Treatment.</title>
        <description>HbA1c is measured as a percentage. The change from baseline is the Week 30 HbA1c minus the baseline HbA1c.</description>
        <time_frame>Baseline and 30 weeks</time_frame>
        <population>Patients from Full Analysis Set (FAS) with last observation carried forward (LOCF) used to handle missing values at Week 30. FAS is the patient set which includes all patients who were documented to have taken at least one dose of treatment and who had a baseline HbA1c value at at least one on-treatment HbA1c.</population>
        <group_list>
          <group group_id="O1">
            <title>Pio15</title>
            <description>Participants treated with pioglitazone 15mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pio30</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O3">
            <title>Pio45</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for 6 weeks and were titrated to pioglitazone 45mg monotherapy for the next 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Participants treated with linagliptin 5mg once daily for the first 30 weeks</description>
          </group>
          <group group_id="O5">
            <title>Lina5Pio15</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O6">
            <title>Lina5Pio30</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O7">
            <title>Lina5Pio45</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 6 weeks and were titrated to linagliptin 5mg + pioglitazone 45mg for the next 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in HbA1c After 30 Weeks of Treatment.</title>
          <description>HbA1c is measured as a percentage. The change from baseline is the Week 30 HbA1c minus the baseline HbA1c.</description>
          <population>Patients from Full Analysis Set (FAS) with last observation carried forward (LOCF) used to handle missing values at Week 30. FAS is the patient set which includes all patients who were documented to have taken at least one dose of treatment and who had a baseline HbA1c value at at least one on-treatment HbA1c.</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="130"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="125"/>
                <count group_id="O7" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.66" spread="0.09"/>
                    <measurement group_id="O2" value="-0.69" spread="0.09"/>
                    <measurement group_id="O3" value="-0.87" spread="0.09"/>
                    <measurement group_id="O4" value="-0.39" spread="0.09"/>
                    <measurement group_id="O5" value="-0.83" spread="0.09"/>
                    <measurement group_id="O6" value="-1.06" spread="0.09"/>
                    <measurement group_id="O7" value="-1.28" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1571</p_value>
            <p_value_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, prior anti-diabetic medication and country.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.41</ci_lower_limit>
            <ci_upper_limit>0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0016</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.41</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>-0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>-0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.12</ci_lower_limit>
            <ci_upper_limit>-0.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of &lt; 7.0% After 30 Weeks of Treatment</title>
        <description>Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.</description>
        <time_frame>Baseline and 30 weeks</time_frame>
        <population>FAS patients who also had baseline HbA1c&gt;=7%.Non-completers (patients without a value at Week 30) were considered as failures (NCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Pio15</title>
            <description>Participants treated with pioglitazone 15mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pio30</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O3">
            <title>Pio45</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for 6 weeks and were titrated to pioglitazone 45mg monotherapy for the next 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Participants treated with linagliptin 5mg once daily for the first 30 weeks</description>
          </group>
          <group group_id="O5">
            <title>Lina5Pio15</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O6">
            <title>Lina5Pio30</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O7">
            <title>Lina5Pio45</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 6 weeks and were titrated to linagliptin 5mg + pioglitazone 45mg for the next 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of &lt; 7.0% After 30 Weeks of Treatment</title>
          <description>Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.</description>
          <population>FAS patients who also had baseline HbA1c&gt;=7%.Non-completers (patients without a value at Week 30) were considered as failures (NCF).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="121"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="129"/>
                <count group_id="O4" value="124"/>
                <count group_id="O5" value="112"/>
                <count group_id="O6" value="118"/>
                <count group_id="O7" value="121"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="68"/>
                    <measurement group_id="O4" value="29"/>
                    <measurement group_id="O5" value="45"/>
                    <measurement group_id="O6" value="61"/>
                    <measurement group_id="O7" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4639</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.246</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.692</ci_lower_limit>
            <ci_upper_limit>2.242</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0546</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.746</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.989</ci_lower_limit>
            <ci_upper_limit>3.083</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0254</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.903</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.083</ci_lower_limit>
            <ci_upper_limit>3.345</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.804</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.524</ci_lower_limit>
            <ci_upper_limit>5.159</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.429</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.947</ci_lower_limit>
            <ci_upper_limit>10.001</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>9.614</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>5.187</ci_lower_limit>
            <ci_upper_limit>17.821</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of &lt; 6.5% After 30 Weeks of Treatment</title>
        <description>Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.</description>
        <time_frame>Baseline and 30 weeks</time_frame>
        <population>FAS patients who also had baseline HbA1c &gt;=6.5%. Non-completers (patients without a value at Week 30) were considered as failures (NCF)</population>
        <group_list>
          <group group_id="O1">
            <title>Pio15</title>
            <description>Participants treated with pioglitazone 15mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pio30</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O3">
            <title>Pio45</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for 6 weeks and were titrated to pioglitazone 45mg monotherapy for the next 24 weeks</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Participants treated with linagliptin 5mg once daily for the first 30 weeks</description>
          </group>
          <group group_id="O5">
            <title>Lina5Pio15</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O6">
            <title>Lina5Pio30</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O7">
            <title>Lina5Pio45</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 6 weeks and were titrated to linagliptin 5mg + pioglitazone 45mg for the next 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Cumulative Treat to Target Efficacy Response, of HbA1c Under Treatment of &lt; 6.5% After 30 Weeks of Treatment</title>
          <description>Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.</description>
          <population>FAS patients who also had baseline HbA1c &gt;=6.5%. Non-completers (patients without a value at Week 30) were considered as failures (NCF)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="132"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="129"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="123"/>
                <count group_id="O7" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="24"/>
                    <measurement group_id="O6" value="38"/>
                    <measurement group_id="O7" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7359</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.126</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.565</ci_lower_limit>
            <ci_upper_limit>2.243</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0363</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.905</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.042</ci_lower_limit>
            <ci_upper_limit>3.484</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4039</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.269</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.726</ci_lower_limit>
            <ci_upper_limit>2.217</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0345</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.220</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.060</ci_lower_limit>
            <ci_upper_limit>4.649</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.580</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.263</ci_lower_limit>
            <ci_upper_limit>9.266</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>5.066</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.530</ci_lower_limit>
            <ci_upper_limit>10.145</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 30 Weeks of Treatment)</title>
        <description>Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.</description>
        <time_frame>Baseline and 30 weeks</time_frame>
        <population>FAS with non-completers (without a value at Week 30) considered as failure</population>
        <group_list>
          <group group_id="O1">
            <title>Pio15</title>
            <description>Participants treated with pioglitazone 15mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pio30</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O3">
            <title>Pio45</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for 6 weeks and were titrated to pioglitazone 45mg monotherapy for the next 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Participants treated with linagliptin 5mg once daily for the first 30 weeks</description>
          </group>
          <group group_id="O5">
            <title>Lina5Pio15</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O6">
            <title>Lina5Pio30</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O7">
            <title>Lina5Pio45</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 6 weeks and were titrated to linagliptin 5mg + pioglitazone 45mg for the next 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Occurrence of Relative Efficacy Response (HbA1c Lowering by at Least 0.5% After 30 Weeks of Treatment)</title>
          <description>Glycosylated hemoglobin is reported as a percentage of the total hemoglobin.</description>
          <population>FAS with non-completers (without a value at Week 30) considered as failure</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="130"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="125"/>
                <count group_id="O7" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79"/>
                    <measurement group_id="O2" value="83"/>
                    <measurement group_id="O3" value="90"/>
                    <measurement group_id="O4" value="54"/>
                    <measurement group_id="O5" value="79"/>
                    <measurement group_id="O6" value="91"/>
                    <measurement group_id="O7" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7540</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.090</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.637</ci_lower_limit>
            <ci_upper_limit>1.863</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0506</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.707</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.999</ci_lower_limit>
            <ci_upper_limit>2.918</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.966</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.604</ci_lower_limit>
            <ci_upper_limit>5.485</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.696</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.594</ci_lower_limit>
            <ci_upper_limit>4.559</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.017</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>2.348</ci_lower_limit>
            <ci_upper_limit>6.873</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>8.521</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>4.630</ci_lower_limit>
            <ci_upper_limit>15.681</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c Change From Baseline by Visit Over Time</title>
        <description>HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes fixed effects for treatment, continuous baseline HbA1c, prior andi-diabetic medication, country, visit and treatment.
by visit interaction.</description>
        <time_frame>Baseline, week 6, week 12, week 18, week 24, week 30</time_frame>
        <population>FAS (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Pio15</title>
            <description>Participants treated with pioglitazone 15mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pio30</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O3">
            <title>Pio45</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for 6 weeks and were titrated to pioglitazone 45mg monotherapy for the next 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Participants treated with linagliptin 5mg once daily for the first 30 weeks</description>
          </group>
          <group group_id="O5">
            <title>Lina5Pio15</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O6">
            <title>Lina5Pio30</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O7">
            <title>Lina5Pio45</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 6 weeks and were titrated to linagliptin 5mg + pioglitazone 45mg for the next 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c Change From Baseline by Visit Over Time</title>
          <description>HbA1c is measured as a percentage. The change from baseline is the HbA1c over time minus the baseline HbA1c. The model includes fixed effects for treatment, continuous baseline HbA1c, prior andi-diabetic medication, country, visit and treatment.
by visit interaction.</description>
          <population>FAS (observed cases)</population>
          <units>percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="130"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="125"/>
                <count group_id="O7" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change to week 6 (N=121,133,133,130,119,124,125)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.06"/>
                    <measurement group_id="O2" value="-0.16" spread="0.06"/>
                    <measurement group_id="O3" value="-0.20" spread="0.06"/>
                    <measurement group_id="O4" value="-0.23" spread="0.06"/>
                    <measurement group_id="O5" value="-0.43" spread="0.06"/>
                    <measurement group_id="O6" value="-0.47" spread="0.06"/>
                    <measurement group_id="O7" value="-0.62" spread="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to week 12 (N=112,124,127,122,111,117,120)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.47" spread="0.08"/>
                    <measurement group_id="O2" value="-0.43" spread="0.07"/>
                    <measurement group_id="O3" value="-0.59" spread="0.07"/>
                    <measurement group_id="O4" value="-0.36" spread="0.08"/>
                    <measurement group_id="O5" value="-0.71" spread="0.08"/>
                    <measurement group_id="O6" value="-0.92" spread="0.08"/>
                    <measurement group_id="O7" value="-1.01" spread="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to week 18 (N=101,121,122,112,104,104,115)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" spread="0.09"/>
                    <measurement group_id="O2" value="-0.58" spread="0.08"/>
                    <measurement group_id="O3" value="-0.82" spread="0.08"/>
                    <measurement group_id="O4" value="-0.39" spread="0.08"/>
                    <measurement group_id="O5" value="-0.81" spread="0.09"/>
                    <measurement group_id="O6" value="-1.07" spread="0.09"/>
                    <measurement group_id="O7" value="-1.22" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to week 24 (N=91,108,110,95,92,96,109)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.75" spread="0.09"/>
                    <measurement group_id="O2" value="-0.67" spread="0.09"/>
                    <measurement group_id="O3" value="-0.87" spread="0.09"/>
                    <measurement group_id="O4" value="-0.39" spread="0.09"/>
                    <measurement group_id="O5" value="-0.84" spread="0.09"/>
                    <measurement group_id="O6" value="-1.10" spread="0.09"/>
                    <measurement group_id="O7" value="-1.23" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change to week 30 (N=78,93,91,79,86,87,97)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="0.09"/>
                    <measurement group_id="O2" value="-0.73" spread="0.08"/>
                    <measurement group_id="O3" value="-0.94" spread="0.09"/>
                    <measurement group_id="O4" value="-0.37" spread="0.09"/>
                    <measurement group_id="O5" value="-0.87" spread="0.09"/>
                    <measurement group_id="O6" value="-1.09" spread="0.09"/>
                    <measurement group_id="O7" value="-1.27" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose (FPG) Change From Baseline After 30 Weeks of Treatment</title>
        <description>The change from baseline is the FPG after 30 weeks minus the baseline FPG.</description>
        <time_frame>Baseline and 30 weeks</time_frame>
        <population>Patients from Full Analysis Set (FAS) with a value for FPG at baseline and on-treatment. Last observation carried forward (LOCF) used to handle missing values at Week 30.</population>
        <group_list>
          <group group_id="O1">
            <title>Pio15</title>
            <description>Participants treated with pioglitazone 15mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pio30</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O3">
            <title>Pio45</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for 6 weeks and were titrated to pioglitazone 45mg monotherapy for the next 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Participants treated with linagliptin 5mg once daily for the first 30 weeks</description>
          </group>
          <group group_id="O5">
            <title>Lina5Pio15</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O6">
            <title>Lina5Pio30</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O7">
            <title>Lina5Pio45</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 6 weeks and were titrated to linagliptin 5mg + pioglitazone 45mg for the next 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG) Change From Baseline After 30 Weeks of Treatment</title>
          <description>The change from baseline is the FPG after 30 weeks minus the baseline FPG.</description>
          <population>Patients from Full Analysis Set (FAS) with a value for FPG at baseline and on-treatment. Last observation carried forward (LOCF) used to handle missing values at Week 30.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="123"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="130"/>
                <count group_id="O5" value="119"/>
                <count group_id="O6" value="123"/>
                <count group_id="O7" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.16" spread="3.49"/>
                    <measurement group_id="O2" value="-25.49" spread="3.28"/>
                    <measurement group_id="O3" value="-28.69" spread="3.29"/>
                    <measurement group_id="O4" value="-1.46" spread="3.35"/>
                    <measurement group_id="O5" value="-18.84" spread="3.47"/>
                    <measurement group_id="O6" value="-27.33" spread="3.46"/>
                    <measurement group_id="O7" value="-35.19" spread="3.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.4275</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, continuous baseline FPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-3.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.77</ci_lower_limit>
            <ci_upper_limit>5.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6839</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, continuous baseline FPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.69</ci_lower_limit>
            <ci_upper_limit>7.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1466</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, continuous baseline FPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-6.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.29</ci_lower_limit>
            <ci_upper_limit>2.28</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, continuous baseline FPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-17.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-26.35</ci_lower_limit>
            <ci_upper_limit>-8.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, continuous baseline FPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-25.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-34.77</ci_lower_limit>
            <ci_upper_limit>-16.98</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c, continuous baseline FPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-42.57</ci_lower_limit>
            <ci_upper_limit>-24.89</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fasting Plasma Glucose (FPG) Change From Baseline by Visit Over Time</title>
        <description>The change from baseline is the FPG over time minus the baseline FPG. Model includes fixed effects for treatment, continuous baseline FPG, continuous baseline HbA1c, prior anti-diabetic medication, country, visit and treatment by visit interaction</description>
        <time_frame>Baseline, week 6, week 12, week 18, week 24, week 30</time_frame>
        <population>FAS (observed cases)</population>
        <group_list>
          <group group_id="O1">
            <title>Pio15</title>
            <description>Participants treated with pioglitazone 15mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pio30</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O3">
            <title>Pio45</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for 6 weeks and were titrated to pioglitazone 45mg monotherapy for the next 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Participants treated with linagliptin 5mg once daily for the first 30 weeks</description>
          </group>
          <group group_id="O5">
            <title>Lina5Pio15</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O6">
            <title>Lina5Pio30</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O7">
            <title>Lina5Pio45</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 6 weeks and were titrated to linagliptin 5mg + pioglitazone 45mg for the next 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Fasting Plasma Glucose (FPG) Change From Baseline by Visit Over Time</title>
          <description>The change from baseline is the FPG over time minus the baseline FPG. Model includes fixed effects for treatment, continuous baseline FPG, continuous baseline HbA1c, prior anti-diabetic medication, country, visit and treatment by visit interaction</description>
          <population>FAS (observed cases)</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="130"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="125"/>
                <count group_id="O7" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at week 6 (N=118,132,133,130,119,122,124)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.43" spread="2.99"/>
                    <measurement group_id="O2" value="-16.38" spread="2.80"/>
                    <measurement group_id="O3" value="-15.72" spread="2.81"/>
                    <measurement group_id="O4" value="-4.25" spread="2.84"/>
                    <measurement group_id="O5" value="-19.25" spread="2.96"/>
                    <measurement group_id="O6" value="-26.89" spread="2.94"/>
                    <measurement group_id="O7" value="-28.36" spread="2.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 12 (N=111,124,126,122,108,114,118)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.63" spread="3.24"/>
                    <measurement group_id="O2" value="-21.36" spread="3.04"/>
                    <measurement group_id="O3" value="-25.30" spread="3.03"/>
                    <measurement group_id="O4" value="-7.43" spread="3.08"/>
                    <measurement group_id="O5" value="-17.99" spread="3.24"/>
                    <measurement group_id="O6" value="-31.25" spread="3.19"/>
                    <measurement group_id="O7" value="-28.53" spread="3.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 18 (N=100,122,121,111,104,103,114)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.68" spread="3.29"/>
                    <measurement group_id="O2" value="-20.69" spread="3.02"/>
                    <measurement group_id="O3" value="-28.68" spread="3.03"/>
                    <measurement group_id="O4" value="-7.06" spread="3.13"/>
                    <measurement group_id="O5" value="-19.01" spread="3.24"/>
                    <measurement group_id="O6" value="-31.22" spread="3.25"/>
                    <measurement group_id="O7" value="-30.66" spread="3.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 24 (N=90,108,108,96,93,93,108)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.25" spread="3.25"/>
                    <measurement group_id="O2" value="-21.57" spread="2.99"/>
                    <measurement group_id="O3" value="-27.67" spread="3.00"/>
                    <measurement group_id="O4" value="-4.60" spread="3.13"/>
                    <measurement group_id="O5" value="-16.68" spread="3.20"/>
                    <measurement group_id="O6" value="-31.48" spread="3.20"/>
                    <measurement group_id="O7" value="-31.49" spread="3.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at week 30 (N=76,91,89,79,82,87,98)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.66" spread="3.35"/>
                    <measurement group_id="O2" value="-26.09" spread="3.08"/>
                    <measurement group_id="O3" value="-31.76" spread="3.11"/>
                    <measurement group_id="O4" value="-0.09" spread="3.24"/>
                    <measurement group_id="O5" value="-17.93" spread="3.27"/>
                    <measurement group_id="O6" value="-27.11" spread="3.22"/>
                    <measurement group_id="O7" value="-34.04" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Two-hour Postprandial Glucose (2hPPG) Change From Baseline at Week 30 by Meal Tolerance Test (MTT)</title>
        <description>The change from baseline is the 2hPPG after 30 weeks minus the baseline 2hPPG.</description>
        <time_frame>Baseline and 30 weeks</time_frame>
        <population>MTT set: This patient set includes those patients in the FAS who had a valid MTT at baseline and at least one valid on-treatment MTT. An MTT is considered valid if both an FPG and a 2-hour PPG value are available.</population>
        <group_list>
          <group group_id="O1">
            <title>Pio15</title>
            <description>Participants treated with pioglitazone 15mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pio30</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O3">
            <title>Pio45</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for 6 weeks and were titrated to pioglitazone 45mg monotherapy for the next 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Participants treated with linagliptin 5mg once daily for the first 30 weeks</description>
          </group>
          <group group_id="O5">
            <title>Lina5Pio15</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O6">
            <title>Lina5Pio30</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O7">
            <title>Lina5Pio45</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 6 weeks and were titrated to linagliptin 5mg + pioglitazone 45mg for the next 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Two-hour Postprandial Glucose (2hPPG) Change From Baseline at Week 30 by Meal Tolerance Test (MTT)</title>
          <description>The change from baseline is the 2hPPG after 30 weeks minus the baseline 2hPPG.</description>
          <population>MTT set: This patient set includes those patients in the FAS who had a valid MTT at baseline and at least one valid on-treatment MTT. An MTT is considered valid if both an FPG and a 2-hour PPG value are available.</population>
          <units>mg/dL</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="22"/>
                <count group_id="O5" value="28"/>
                <count group_id="O6" value="26"/>
                <count group_id="O7" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.65" spread="10.93"/>
                    <measurement group_id="O2" value="-83.00" spread="9.85"/>
                    <measurement group_id="O3" value="-82.98" spread="10.92"/>
                    <measurement group_id="O4" value="-51.61" spread="11.67"/>
                    <measurement group_id="O5" value="-67.26" spread="11.15"/>
                    <measurement group_id="O6" value="-87.94" spread="11.14"/>
                    <measurement group_id="O7" value="-84.77" spread="10.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0057</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c and 2-hour PPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-36.61</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-62.42</ci_lower_limit>
            <ci_upper_limit>-10.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7021</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c and 2-hour PPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-4.94</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-30.39</ci_lower_limit>
            <ci_upper_limit>20.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.8932</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c and 2-hour PPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.78</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27.95</ci_lower_limit>
            <ci_upper_limit>24.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2706</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c and 2-hour PPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-15.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.60</ci_lower_limit>
            <ci_upper_limit>12.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0126</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c and 2-hour PPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-36.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-64.78</ci_lower_limit>
            <ci_upper_limit>-7.89</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0167</p_value>
            <method>ANCOVA</method>
            <method_desc>The model includes fixed effects for treatment, continuous baseline HbA1c and 2-hour PPG, prior anti-diabetic medication and country.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-33.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-60.23</ci_lower_limit>
            <ci_upper_limit>-6.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Use of Rescue Therapy</title>
        <description>Proportion of patients at 30 weeks with rescue therapy using Kaplan-Meier analysis.</description>
        <time_frame>30 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pio15</title>
            <description>Participants treated with pioglitazone 15mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pio30</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O3">
            <title>Pio45</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for 6 weeks and were titrated to pioglitazone 45mg monotherapy for the next 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Participants treated with linagliptin 5mg once daily for the first 30 weeks</description>
          </group>
          <group group_id="O5">
            <title>Lina5Pio15</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O6">
            <title>Lina5Pio30</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O7">
            <title>Lina5Pio45</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 6 weeks and were titrated to linagliptin 5mg + pioglitazone 45mg for the next 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Use of Rescue Therapy</title>
          <description>Proportion of patients at 30 weeks with rescue therapy using Kaplan-Meier analysis.</description>
          <population>FAS</population>
          <units>Proportion of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="130"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="125"/>
                <count group_id="O7" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Proportion event-free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8117" spread="50.5"/>
                    <measurement group_id="O2" value="0.8533" spread="47.8"/>
                    <measurement group_id="O3" value="0.9051" spread="55.3"/>
                    <measurement group_id="O4" value="0.7756" spread="47.7"/>
                    <measurement group_id="O5" value="0.8854" spread="61.5"/>
                    <measurement group_id="O6" value="0.9078" spread="54.7"/>
                    <measurement group_id="O7" value="0.9548" spread="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Standard Error</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0382"/>
                    <measurement group_id="O2" value="0.0330"/>
                    <measurement group_id="O3" value="0.0273"/>
                    <measurement group_id="O4" value="0.0390"/>
                    <measurement group_id="O5" value="0.0313"/>
                    <measurement group_id="O6" value="0.0279"/>
                    <measurement group_id="O7" value="0.0198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Rescue Therapy During the First 30 Weeks of Treatment</title>
        <description>Rescue therapy was defined to include any new antidiabetic medication taken for hyperglycemia and introduced on or after the start date of study treatment and before the end date of study treatment.</description>
        <time_frame>30 weeks</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Pio15</title>
            <description>Participants treated with pioglitazone 15mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O2">
            <title>Pio30</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for the first 30 weeks</description>
          </group>
          <group group_id="O3">
            <title>Pio45</title>
            <description>Participants treated with pioglitazone 30mg monotherapy for 6 weeks and were titrated to pioglitazone 45mg monotherapy for the next 24 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Lina5</title>
            <description>Participants treated with linagliptin 5mg once daily for the first 30 weeks</description>
          </group>
          <group group_id="O5">
            <title>Lina5Pio15</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O6">
            <title>Lina5Pio30</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 30 weeks</description>
          </group>
          <group group_id="O7">
            <title>Lina5Pio45</title>
            <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for the first 6 weeks and were titrated to linagliptin 5mg + pioglitazone 45mg for the next 24 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Rescue Therapy During the First 30 Weeks of Treatment</title>
          <description>Rescue therapy was defined to include any new antidiabetic medication taken for hyperglycemia and introduced on or after the start date of study treatment and before the end date of study treatment.</description>
          <population>FAS</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="124"/>
                <count group_id="O2" value="134"/>
                <count group_id="O3" value="134"/>
                <count group_id="O4" value="130"/>
                <count group_id="O5" value="120"/>
                <count group_id="O6" value="125"/>
                <count group_id="O7" value="126"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="26"/>
                    <measurement group_id="O5" value="12"/>
                    <measurement group_id="O6" value="10"/>
                    <measurement group_id="O7" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3052</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.649</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.284</ci_lower_limit>
            <ci_upper_limit>1.482</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0844</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.456</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.187</ci_lower_limit>
            <ci_upper_limit>1.112</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1561</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.443</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.143</ci_lower_limit>
            <ci_upper_limit>1.365</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0146</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.368</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.165</ci_lower_limit>
            <ci_upper_limit>0.821</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O6</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0009</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.238</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.102</ci_lower_limit>
            <ci_upper_limit>0.557</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
            </group_id_list>
            <groups_desc>Treatment comparisons are for fixed dose combination versus monotherapy.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Regression, Logistic</method>
            <method_desc>A logistic regression model with terms for treatment, continuous HbA1c baseline, prior use of antidiabetic agents and country.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.141</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.050</ci_lower_limit>
            <ci_upper_limit>0.397</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 85 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pio15/Pio30</title>
          <description>Participants treated with pioglitazone 15mg for 30 weeks followed by pioglitazone 30mg for up to 54 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Pio30/Pio30</title>
          <description>Participants treated with pioglitazone 30mg for 30 weeks followed by pioglitazone 30mg for up to 54 weeks.</description>
        </group>
        <group group_id="E3">
          <title>Pio45/Pio45</title>
          <description>Participants treated with pioglitazone 30 mg for 6 weeks and then were titrated up to pioglitazone 45mg for 24 weeks followed by pioglitazone 45mg for up to 54 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Lina5/Lina5</title>
          <description>Participants treated with linagliptin 5mg once daily for 30 weeks followed by linagliptin 5mg once daily for up to 54 weeks.</description>
        </group>
        <group group_id="E5">
          <title>Lina5Pio15/Lina5Pio30</title>
          <description>Participants treated with linagliptin 5mg + pioglitazone 15mg fixed dose combination (FDC) for 30 weeks followed by linagliptin 5mg + pioglitazone 30mg FDC for up to 54 weeks.</description>
        </group>
        <group group_id="E6">
          <title>Lina5Pio30/Lina5Pio30</title>
          <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for 30 weeks followed by linagliptin 5mg + pioglitazone 30mg FDC for up to 54 weeks.</description>
        </group>
        <group group_id="E7">
          <title>Lina5Pio45/Lina5Pio45</title>
          <description>Participants treated with linagliptin 5mg + pioglitazone 30mg fixed dose combination (FDC) for 6 weeks and linagliptin 5mg + pioglitazone 45mg FDC for 24 weeks followed by linagliptin 5mg + pioglitazone 45mg FDC for up to 54 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MEDDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Idiopathic thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal artery embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastric haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Anaemia postoperative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Traumatic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hairy cell leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Rectosigmoid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Renal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Small intestine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Tumour invasion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Peripheral nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Gastric bypass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Vascular graft</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Aortic stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Arteriovenous fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MEDDRA 15.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="66" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="52" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="58" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="56" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="11" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="133"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="131"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="140"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="138"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="135"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="126"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="133"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="133"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study (Part B treatment only) was stopped early by protocol amendment #5, although Part A (time frame for all efficacy outcomes) proceeded to completion</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

